ArticleMolecular biomedicine2026
Matricellular protein SMOC2 safeguards tubular integrity in acute kidney injury via integrin β3-dependent inhibition of CCND1-CDK4/6 axis.
Article in Molecular biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrating machine learning, deep learning, and docking to predict aristolochic acid A carcinogenesis.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Tubular injury during acute kidney injury (AKI) is a major determinant of chronic kidney disease (CKD) progression, yet the molecular mechanisms underlying tubular protection remain incompletely understood. Here, we identify the matricellular protein SPARC-related modular calcium-binding 2 (SMOC2) as a previously unrecognized protective regulator of tubular injury. Although SMOC2 has been implicated in renal fibrosis through fibroblast activation, its role during AKI remains unknown. We show that SMOC2 expression is rapidly and robustly induced in renal tubules following exposure to aristolochic acid I (AAI) or cisplatin. Unexpectedly, SMOC2 knockout mice exhibited aggravated tubular injury, increased DNA damage and apoptosis, and worsened renal function in both AAI- and cisplatin-induced AKI models, whereas recombinant SMOC2 (rSMOC2) treatment markedly ameliorated AAI-induced tubular injury. Furthermore, in an AAI-induced AKI-to-CKD model, SMOC2 deficiency exacerbated renal fibrosis, linking early tubular protection to long-term outcomes. Mechanistically, transcriptomic profiling and biochemical analyses revealed that SMOC2 suppresses aberrant G1/S cell cycle progression by restraining the CCND1-CDK4/6 axis through its interaction with integrin β3 (ITGB3), thereby arresting tubular cells in the G1 phase and facilitating DNA repair. This interaction depends on the cooperation of multiple structural domains rather than a single motif. Notably, pharmacological inhibition of CDK4/6 with palbociclib phenocopied the protective effects of SMOC2, with post-injury treatment providing superior protection, thus defining a druggable downstream pathway. Collectively, our findings uncover a previously unappreciated cytoprotective role of SMOC2 in AKI and establish the SMOC2-ITGB3-CCND1-CDK4/6 signaling axis as a potential therapeutic target to prevent AKI progression and its transition to CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.